Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
复制标题
DOI：
10.1054/bjoc.2000.1716
复制
发表时间：
2001-04-06
影响因子：
8.8
通讯作者：
Matsuzawa, Y
中科院分区：
文献类型：
--
作者：
Kawata, S;Yamasaki, E;Matsuzawa, Y
化疗对肝细胞癌（HCC）无效。HMG-CoA还原酶抑制剂对癌细胞具有细胞抑制活性，但其临床用途尚不清楚。为了研究普伐他汀（一种有效的HMG-CoA还原酶抑制剂）是否延长晚期HCC患者的生存期，这项随机对照试验于1990年2月至1998年2月在大坂大学医院进行。91例连续患者
Chemotherapy is not effective for hepatocellular carcinoma (HCC). HMG-CoA redutase inhibitors have cytostatic activity for cancer cells, but their clinical usefulness is unknown. To investigate whether pravastatin, a potent HMG-CoA reductase inhibitor, prolongs survival in patients with advanced HCC, this randomized controlled trial was conducted between February 1990 and February 1998 at Osaka University Hospital. 91 consecutive patients